Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)
Status:
Terminated
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This is the sister study to the BMS "Cognitive Improvement with Aripiprazole (Abilify)" study
(LSUHSC #H04-022). Evaluation of cognitive ability in patients with schizophrenia or
schizoaffective disorder both before and after a switch from risperidone, olanzapine, or
risperidone Consta injections to aripiprazole may reveal some of the cognitive changes that
correlate with the improved response, better side effect profile, and effects on other
components of the negative symptom array. Further, examination of brain functional activity
using functional magnetic resonance imaging (fMRI) during an episodic memory task, as well as
behavioral performance and associated electroencephalographic (EEG) data of working memory
and intermediate term verbal memory collected with the Sustained Attention and Memory Brain
Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes
in cognition.
Phase:
N/A
Details
Lead Sponsor:
Louisiana State University Health Sciences Center Shreveport
Collaborator:
SAM Technology & The San Francisco Brain Research Institute